

Claims

1. Pharmaceutical compositions, comprising two or more substances of the group of  $\alpha$ -lipoic acid and its salts and isomers, ambroxol and its salts and prodrugs and inhibitors of the angiotensin-converting enzyme (ACE), optionally together with usual pharmaceutically acceptable carriers, additives and adjuvants.  
5
- 10 2. Pharmaceutical compositions according to claim 1, comprising a combination of  $\alpha$ -lipoic acid or its salts or its isomers and of ambroxol or its salts or its prodrugs.
- 15 3. Pharmaceutical compositions according to claim 1, comprising a combination of  $\alpha$ -lipoic acid or its salts or its isomers and of at least one inhibitor of the angiotensin-converting enzyme.
- 20 4. Pharmaceutical compositions according to claim 1, comprising a combination of ambroxol or its salts or its prodrugs and of at least one inhibitor of the angiotensin-converting enzyme.
- 25 5. Pharmaceutical compositions according to any of the claims 1 to 4, comprising a combination of  $\alpha$ -lipoic acid or its salts or its isomers and of ambroxol or its salts or its prodrugs and of at least one inhibitor of the angiotensin-converting enzyme.

6. Pharmaceutical compositions according to any of the claims 1 to 5, additionally comprising one or several known carriers, adjuvants and/or additives.
- 5 7. Pharmaceutical compositions according to any of the claims 1 to 6, comprising  $\alpha$ -lipoic acid or its salts or its isomers in amounts in the range of from 30 to 1,200 mg/day, preferably in the range of from 200 to 600 mg/day, and/or ambroxol or its salts or its prodrugs in amounts in the range of  
10 from 7.5 to 90 mg/day, preferably in the range of from 60 to 75 mg/day, and/or at least one inhibitor of the angiotensin-converting enzyme in amounts in the range of from 1 to 50 mg/day, preferably in the range of from 5 to 20 mg/day.
- 15 8. Pharmaceutical compositions according to any of the claims 1 to 7 for an oral, buccal, pulmonal, nasal, transdermal, intravenous, subcutaneous, intracutaneous, intramuscular, rectal, vaginal and intrathecal administration.
- 20 9. Pharmaceutical compositions according to any of the claims 1 to 7 in the form of tablets, powders, granulates, capsules, solutions, emulsions, suspensions, aerosols, transdermal application systems, suppositories and administration forms  
25 having a retarded release of single or all effective agents.
10. Use of the pharmaceutical compositions according to one or several of the claims 1 to 9 for a

prevention and a therapy of neurodegenerative diseases.

11. Use according to claim 10 for a prevention and a therapy of the diseases ischemic or hemorrhagic stroke, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, Hunntington's disease, multiple sclerosis, neurodegeneration of aged people, dementia, cranial cerebral trauma, and Autosomal Dominant Neurohypophyseal Diabetes Insipidus.
12. Use according to claim 10 for a prevention and a therapy of cerebral ischemia resulting from cardial and cardiovascular insults.